(6-346) Relative Efficacy and Safety of Sotagliflozin, Empagliflozin, Canagliflozin, and Dapagliflozin in Patients with Type 2 Diabetes and Established Cardiovascular Disease: An Indirect Treatment Comparison
Tuesday, December 10, 2024
10:45 AM – 11:45 AM
Location: Hall G, Lower Level
Category: Evaluative Study Topic: Clinical Topics/Therapeutics
Co-Author(s): Katelyn Ditch, Jordan Franklin, Ismaeel Yunusa
